Sonico-CX provides a safe and effective option for treating calcified coronary lesions. SINGAPORE, Jan. 6, 2026 /PRNewswire/ -- Spectrumedics Medical (hereinafter "Spectrumedics") is pleased to announce that its Sonico-CX Intravascular Lithotripsy (IVL) System has obtained CE Mark certification under the European Union Medical Device Regulation (EU MDR). The system comprises the Sonico-CX Coronary Intravascular Lithotripsy Catheter and the Intravascular Lithotripsy Generator. The CE Mark was iss

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Azstarys®) for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older in China. Continue Reading Figure 1. Each Azstarys® capsule contains 70% SDX and 30% d-MPH Azstary

Weeks after the FDA approved the first oral GLP-1 agonist, Eli Lilly wasted little time in expanding its own oral weight-loss drug ambitions. The company entered a multi-year research collaboration and licensing agreement with Nimbus Therapeutics that could be worth more than $1.3 billion.The deal deepens an ongoing partnership worth up to $496 million that began in 2022 when the two companies partnered to develop small-molecule activators of AMP-activated protein kinase for cardiometabolic diso

Amgen acquired University of Oxford spinout Dark Blue Therapeutics under a deal valued at up to $840 million, expanding its oncology pipeline with the addition of a preclinical protein degrader for treating acute myeloid leukaemia (AML). While specific terms of the agreement were not disclosed, the transaction includes upfront and future milestones.Dark Blue Therapeutics' lead candidate, dubbed DBT 3757, is a small molecule degrader of the transcriptional regulator MLLT 1/3 that is currently in

Alumis announced Tuesday that a pair of Phase III studies of the oral TYK2 inhibitor envudeucitinib in plaque psoriasis met all of their primary and secondary endpoints. The news sent the company's shares up nearly as much as 18% in pre-market trading. "These pivotal data strengthen our conviction in envudeucitinib's potential to transform the treatment landscape for IL‑23/IL‑17–driven diseases," said CEO Martin Babler, who suggested that the drug's "highly differentiated clinical profile positi

Incyte's Monjuvi (tafasitamab) met the primary endpoint of a pivotal study for the first-line treatment of adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL), setting up a marketing application to the FDA in the first half of the year. The Phase III frontMIND trial enrolled around 900 adults with newly diagnosed DLBCL with an International Prognostic Index (IPI) score of three to five for patients >60 years of age, or age-adjusted IPI of two to three for patients ≤60 years of age.

SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster's cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering run

HUMMELSTOWN, Pa., Jan. 5, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Sinisa Dovat, MD, Ph.D. is acknowledged as a Pinnacle Lifetime Member for his contributions in Pediatric Hematology-Oncology. Dr. Sinisa Dovat is a distinguished physician scientist specializing in the development of therapeutics for high-risk pediatric leukemia. With a career at the forefront of treatment innovations, Dr. Dovat integrates clinical medicine with disease mechanisms to advance thera

Rebrand announced in June as part of Fujifilm Life Sciences Group restructuring becomes official FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences, providing a full spectrum of life sciences solutions built from a 55-year history as a cell culture pioneer. SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced the Company has officially changed its legal name from FUJ

MIAMI--(BUSINESS WIRE)-- $SMMT --Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 44 th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President and Co-Chief Executive Officer, will present a corporate overview and a new update on the progress of our organizati